Pharmaceutical

BeiGene (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced the pricing of its follow-on public offering of 7,425,750 American Depositary Shares (ADSs), each representing 13 of its ordinary shares, par value $0.0001 per share, at a price to the public …

BeiGene (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced the pricing of its follow-on public offering of 7,425,750 American Depositary Shares (ADSs), each representing 13 of its ordinary shares, par value $0.0001 per share, at a price to the public of $101.00 per ADS.
As quoted in the press release:

BeiGene intends to use proceeds from the offering for working capital and general corporate purposes, including research and development activities.
Goldman Sachs & Co. LLC, Morgan Stanley, Cowen, and Leerink Partners are acting as joint book-running managers. William Blair & Company, L.L.C. is acting as the co-manager.

Click here to read the full press release.

MARKETS

Markets
TSX19532.38+27.05
TSXV652.69-2.07
DOW32745.43+349.26
S&P 5004143.58+52.39
NASD12607.68+258.92
ASX6998.10+5.10

COMMODITIES

Commodities
Gold1757.44+1.10
Silver19.90+0.04
Copper3.46-0.06
Palladium2010.00-44.00
Platinum898.50+6.50
Oil91.92-2.50
Heating Oil3.43+0.05
Natural Gas7.66-0.05

DOWNLOAD FREE REPORTS

×